Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Hepatology. 2021 May 24;74(3):1411–1428. doi: 10.1002/hep.31817

Figure 7: SULF2 monoclonal antibody 5D5 inhibits PDGFRβ-YAP signaling in vivo.

Figure 7:

(A) Western blot of xenograft tissue protein extracts showed that treatment with anti-SULF2 5D5 antibody significantly reduced the levels of phospho-PDGFRβ, phospho-YAPY357, total YAP and Cyclin D1 compared to IgG treated xenografts (n=5,5). (B) Representative IF images of HuCCT1 tumor xenografts treated with control IgG and anti-SULF2 5D5 antibody stained for phospho-YAPY357 (green), and DAPI (Blue). 400×.